Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Questcor Securities Litigation
Case Number:
8:12-cv-01623
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Barrett Johnston
- Berman Tabacco
- Glancy Prongay
- Holzer & Holzer
- Johnson Fistel
- Kessler Topaz
- Latham & Watkins
- Law Office of Thomas J. Nolan
- Reid & Wise
- Robbins Geller
- Skadden Arps
Companies
Sectors & Industries:
-
April 13, 2015
Questcor Pays $38M To Settle Securities Class Action
Questcor Pharmaceuticals Inc. on Monday agreed to pay $38 million to end a consolidated securities class action alleging the company lies about the efficacy of its biggest moneymaker, multiple sclerosis drug Acthar.
-
November 13, 2014
Questcor Securities Class Clinches Certification
A California federal judge certified a pension fund and investor class Wednesday in litigation accusing Questcor Pharmaceuticals Inc. of misrepresenting the prospects of its multiple sclerosis drug Acthar.
-
October 02, 2013
Questcor Can't Kick Securities Fraud Case
A California federal judge on Tuesday kept alive most of a securities fraud class action against Questcor Pharmaceuticals Inc., finding investors had sufficiently alleged the company had misrepresented the clinical support for its Acthar drug and the stability of insurance reimbursement rates.